Sernova (TSE:SVA) Stock Price Down 2.8% - Should You Sell?

Key Points

• Sernova Corp.'s stock price fell by 2.8% to C$0.18, with trading volume declining by 98% compared to its average daily volume.
• The company has a market capitalization of C$57.48 million and a debt-to-equity ratio of -4.40, indicating a challenging financial position.
• Sernova is a clinical-stage biotherapeutics company focused on developing bio-hybrid organs that integrate living cells to restore organ function.

Sernova Corp. (TSE:SVA - Get Free Report) dropped 2.8% on Thursday . The company traded as low as C$0.18 and last traded at C$0.18. Approximately 2,500 shares traded hands during mid-day trading, a decline of 98% from the average daily volume of 129,170 shares. The stock had previously closed at C$0.18.

Sernova Price Performance

The company has a quick ratio of 18.11, a current ratio of 0.32 and a debt-to-equity ratio of -4.40. The firm has a market capitalization of C$64.05 million, a price-to-earnings ratio of -2.79 and a beta of 0.78. The stock's 50 day moving average price is C$0.18 and its two-hundred day moving average price is C$0.18.

About Sernova

Sernova Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cells to create a bio-hybrid organ. A bio-hybrid organ refers to a medical device designed to be implanted into the human body, where it integrates with existing living tissue to replicate or enhance the function of a natural organ, essentially aiming to restore normal organ function by combining living cells with non-living materials to mimic the properties of the original organ and seamlessly interact with surrounding tissues.